Abstract:Chimeric antigen receptor T (CAR-T) cell therapy has transformed the field of immunology by redirecting T lymphocytes toward tumor antigens. Despite successes in attaining high remission rates as high as 90%, the performance of CAR therapy is limited by the survival of T cells. T cell persistence is crucial as it sustains immune response against malignancies, playing a critical role in cancer treatment outcomes. This review explores various approaches to improve CAR-T cell persistence, focusing on the choice between autologous and allogeneic cell sources, optimization of culture conditions for T cell subsets, metabolite adjustments to modify T cell metabolism, the use of oncolytic viruses (OVs), and advancements in CAR design. Autologous CAR-T cells generally exhibit longer persistence but are less accessible and cost-effective than their allogeneic counterparts. Optimizing culture conditions by promoting TSCM and TCM cell differentiation has also demonstrated increased persistence, as seen with the use of cytokine combinations like IL-7 and IL-15. Metabolic adjustments, such as using 2-deoxy-D-glucose (2-DG) and L-arginine, have enhanced the formation of memory T cells, leading to improved antitumor activity. OVs, when combined with CAR-T therapy, can amplify CAR-T cell penetration and persistence in solid tumors, although further clinical validation is needed. Advances in CAR design from second to fifth generations have progressively improved T cell activation and survival, with fifth-generation CARs demonstrating strong cytokine-mediated signaling and long-lasting persistence. Understanding the underlying mechanisms behind these strategies is essential for maximizing the potential of CAR-T therapy in treating cancer. Further research is needed to improve safety and efficacy and seamlessly integrate the discussed strategies into the manufacturing process.

Analysis of causes for poor persistence of CAR-T cell therapy in vivo

Strategies to enhance CAR-T persistence

Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence

Current strategies to improve CAR-T cell persistence

A Powerful Strategy to Improve CAR-T Cell Persistence

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

Engineering Better Chimeric Antigen Receptor T Cells

Strategies for Improving CAR T Cell Persistence in Solid Tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

Research status on immunogenicity of chimeric antigen receptor T cell immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy

Relapse after CAR-T Cell Therapy in B-cell Malignancies: Challenges and Future Approaches

CAR trafficking does matter: prospects of ‘Chimeric antigen receptor designed to prevent ubiquitination and downregulation showed durable antitumor efficacy’

Recent advances in CAR-T cell engineering